Estimaciones de analistas de Wall Street para Sutro Biopharma, Inc. (STRO): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-1.66 | ||
| 2026-08-12 | $-2.33 | $-2.19 | -6.4% |
| 2026-05-14 | $-2.94 | $-2.32 | -26.7% |
| 2026-03-23 | $-5.29 | $-8.16 | +35.2% |
| 2025-11-06 | $-6.70 | $-3.94 | -69.9% |
| 2025-08-07 | $-1.40 | $-3.82 | +63.4% |
| 2025-05-08 | $-9.10 | $-6.30 | -44.4% |
| 2025-03-13 | $-8.90 | $-8.30 | -7.2% |
Ratios de valoración
| Precio / Valor contable | -2.10 |
| EV / EBITDA | -0.89 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $59.7M | $51.7M | $38.4M | $42.7M | $42.7M | $61.9M | $67.8M | $153.7M | $62.0M | $102.5M |
| Coste de Ventas | $43.5M | $51.9M | $54.3M | 0 | $77.0M | $9.8M | $8.3M | $6.8M | $7.2M | $7.3M |
| Beneficio Bruto | $16.2M | -$156000 | -$15.8M | $42.7M | -$34.2M | $52.1M | $59.5M | $146.9M | $54.8M | $95.2M |
| I+D | $43.5M | $54.6M | $54.3M | $65.6M | $77.0M | $104.4M | $137.2M | $180.4M | $252.0M | $166.4M |
| Generales y Administrativos | $14.8M | $16.4M | $21.4M | $32.6M | $36.8M | $56.0M | $59.5M | $62.6M | $48.5M | $41.0M |
| Gastos Operativos | $58.4M | $71.0M | $75.6M | $98.2M | $36.8M | $150.6M | $188.4M | $236.2M | $293.3M | $200.1M |
| Beneficio Operativo | $1.4M | -$19.3M | -$37.2M | -$55.5M | -$71.1M | -$98.5M | -$128.9M | -$89.3M | -$238.5M | -$105.0M |
| EBITDA | $7.4M | -$14.1M | -$32.8M | -$46.6M | -$23.8M | -$97.6M | -$105.1M | -$67.9M | -$180.5M | -$145.6M |
| Gastos por Intereses | 0 | $689000 | $1.6M | $4.3M | $4.0M | $3.1M | $3.3M | $23.8M | $31.1M | $38.2M |
| Beneficio Antes de Impuestos | $1.7M | -$19.7M | -$35.3M | -$55.7M | -$32.1M | -$105.5M | -$116.7M | -$88.6M | -$225.1M | -$191.2M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | $2.5M | $18.2M | $2.4M | -$93000 |
| Beneficio Neto | $1.7M | -$19.7M | -$35.3M | -$55.7M | -$32.1M | -$105.5M | -$119.2M | -$106.8M | -$227.5M | -$191.1M |
| BPA | $38.60 | $-28.10 | $-15.50 | $-24.30 | $-9.90 | $-22.90 | $-23.50 | $-17.80 | $-29.60 | $-22.49 |
| BPA Diluido | $38.60 | $-28.10 | $-15.40 | $-24.30 | $-9.90 | $-22.90 | $-23.50 | $-17.80 | $-29.60 | $-22.49 |
| Acciones en Circulación (Diluidas) | $44120 | $699739 | $2.3M | $2.3M | $3.3M | $4.6M | $5.1M | $6.0M | $7.7M | $8.5M |
Precio
| Precio | $15.60 |
| Capitalización | $151M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ADVM · ARTV · CNTB · DTIL · GUTS · IFRX · KLRS
Explorar sector: Healthcare · Biotechnology
Más secciones de STRO: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones